Clinical Trials · NCT00076362

Pediatric Hypothalamic Obesity

CompletedPhase 4Octreotide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Novartis Pharmaceuticals
Enrollment
60
Start date
Mar 2004
Locations
15 sites, United States
Primary endpoint
Change from baseline in BMI
View Octreotide compound reference